Literature DB >> 10951221

Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides.

C Durinx1, A M Lambeir, E Bosmans, J B Falmagne, R Berghmans, A Haemers, S Scharpé, I De Meester.   

Abstract

Dipeptidyl peptidase IV (DPPIV, EC 3.4.14.5) is a serine type protease with an important modulatory activity on a number of chemokines, neuropeptides and peptide hormones. It is also known as CD26 or adenosine deaminase (ADA; EC 3.5.4.4) binding protein. DPPIV has been demonstrated on the plasmamembranes of T cells and activated natural killer or B cells as well as on a number of endothelial and differentiated epithelial cells. A soluble form of CD26/DPPIV has been described in serum. Over the past few years, several related enzymes with similar dipeptidyl peptidase activity have been discovered, raising questions on the molecular origin(s) of serum dipeptidyl peptidase activity. Among them attractin, the human orthologue of the mouse mahogany protein, was postulated to be responsible for the majority of the DPPIV-like activity in serum. Using ADA-affinity chromatography, it is shown here that 95% of the serum dipeptidyl peptidase activity is associated with a protein with ADA-binding properties. The natural protein was purified in milligram quantities, allowing molecular characterization (N-terminal sequence, glycosylation type, CD-spectrum, pH and thermal stability) and comparison with CD26/DPPIV from other sources. The purified serum enzyme was confirmed as CD26.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10951221     DOI: 10.1046/j.1432-1327.2000.01634.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  69 in total

1.  Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.

Authors:  F Vittone; A Liberman; D Vasic; R Ostertag; M Esser; D Walcher; A Ludwig; N Marx; M Burgmaier
Journal:  Diabetologia       Date:  2012-05-18       Impact factor: 10.122

2.  Comparison of two commercial ELISAs against an in-house ELISA for measuring soluble CD26 in human serum.

Authors:  Kei Ohnuma; Tatsuhiko Saito; Ryou Hatano; Osamu Hosono; Satoshi Iwata; Nam H Dang; Hiroki Ninomiya; Chikao Morimoto
Journal:  J Clin Lab Anal       Date:  2014-03-28       Impact factor: 2.352

3.  Degradation of Incretins and Modulation of Blood Glucose Levels by Periodontopathic Bacterial Dipeptidyl Peptidase 4.

Authors:  Yuko Ohara-Nemoto; Manami Nakasato; Yu Shimoyama; Tomomi T Baba; Takeshi Kobayakawa; Toshio Ono; Takashi Yaegashi; Shigenobu Kimura; Takayuki K Nemoto
Journal:  Infect Immun       Date:  2017-08-18       Impact factor: 3.441

Review 4.  Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.

Authors:  C Klemann; L Wagner; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-05-13       Impact factor: 4.330

5.  Quantification of intact and truncated stromal cell-derived factor-1α in circulation by immunoaffinity enrichment and tandem mass spectrometry.

Authors:  Weixun Wang; Bernard K Choi; Wenyu Li; Zhege Lao; Anita Y H Lee; Sandra C Souza; Nathan A Yates; Timothy Kowalski; Alessandro Pocai; Lucinda H Cohen
Journal:  J Am Soc Mass Spectrom       Date:  2014-02-06       Impact factor: 3.109

6.  Distribution of dipeptidyl peptidase IV in patients with chronic tonsillitis.

Authors:  Milan Stankovic; Predrag Vlahovic; Verica Avramovic; Miroljub Todorovic
Journal:  Clin Vaccine Immunol       Date:  2008-04-02

7.  CD26 protease inhibition improves functional response of unfractionated cord blood, bone marrow, and mobilized peripheral blood cells to CXCL12/SDF-1.

Authors:  Kent W Christopherson; Robin R Frank; Sucheta Jagan; Laura A Paganessi; Stephanie A Gregory; Henry C Fung
Journal:  Exp Hematol       Date:  2012-07-27       Impact factor: 3.084

Review 8.  T-cell activation via CD26 and caveolin-1 in rheumatoid synovium.

Authors:  Kei Ohnuma; Hiroshi Inoue; Masahiko Uchiyama; Tadanori Yamochi; Osamu Hosono; Nam H Dang; Chikao Morimoto
Journal:  Mod Rheumatol       Date:  2006       Impact factor: 3.023

9.  Dipeptidyl peptidase IV and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Vivian C Luft; Maria Inês Schmidt; James S Pankow; Ron C Hoogeveen; David Couper; Gerardo Heiss; Bruce B Duncan
Journal:  Diabetes Care       Date:  2010-02-25       Impact factor: 19.112

10.  Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation.

Authors:  W T Arscott; A E LaBauve; V May; U V Wesley
Journal:  Oncogene       Date:  2008-11-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.